Sanofi SA
SNYToday
-0.04%
5 Days
-2.25%
1 Month
-1.58%
6 Months
-2.79%
Year to Date
-2.39%
1 Year
-5.28%
Sanofi SA Stock (SNY) Moved Down by 5.57% on May 4: What Investors Need To Know
• Sanofi stock fell due to Morgan Stanley downgrade and ex-dividend. • Analyst concerns about pipeline growth before 2027 impacted sentiment. • Ex-dividend date caused a technical price adjustment, not performance change.
Sanofi SA Stock (SNY) Moved Up by 4.11% on Mar 26: What Investors Need To Know
• Sanofi stock rose due to positive drug pipeline and regulatory news. • Dupixent approved in Japan for bullous pemphigoid, expanding market reach. • FDA granted Breakthrough Therapy designation for venglustat for Gaucher disease.
Sanofi SA Stock (SNY) Moved Up by 3.33% on Mar 25: Key Drivers Unveiled
• FDA grants Breakthrough Therapy designation to venglustat for Gaucher disease. • Japan approves Dupixent for bullous pemphigoid treatment in adults. • Sanofi acquires global rights to autoimmune disease antibody KT501.
Sanofi SA Stock (SNY) Moved Up by 3.07% on Mar 19: Key Drivers Unveiled
• Sanofi's venglustat received FDA Breakthrough Therapy designation for Gaucher disease. • Dupixent gained FDA approval for allergic fungal rhinosinusitis. • Sanofi announced a €1 billion share buyback and opened a China innovation center.
Sanofi SA's Score
Media Coverage
Analyst Rating
Sanofi SA Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Sanofi SA Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Dodge & Cox | 2.34% |
| Fisher Investments | 0.47% |
| Barrow Hanley Global Investors | 0.29% |
| Managed Account Advisors LLC | 0.24% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor/Hedge Fund | 4.48% |
| Investment Advisor | 3.74% |
| Research Firm | 0.76% |
| Hedge Fund | 0.25% |
Related Instruments
Popular Instruments
